Human Adipocyte Fatty Acid-Binding Protein (aP2) Gene Promoter-Driven Reporter Assay Discriminates Nonlipogenic Peroxisome Proliferator-Activated Receptor γ Ligands

Peroxisome proliferator-activated receptors (PPARs) regulate storage and catabolism of fats and carbohydrates. PPARγ activity increases insulin sensitivity and adipocyte differentiation at the expense of adipogenesis and weight gain. The goal of this study was to 1) clone the promoter of the human adipocyte fatty acid binding protein (aP2) gene, namely fatty acid-binding protein-4, 2) characterize its pharmacological regulation, and 3) determine its putative predictability for adipogenesis. Among the selected PPAR agonists, rosiglitazone and pioglitazone displayed the highest maximal efficacy (Emax) on reporter-gene assays in COS-7 cells cotransfected by either a galactosidase 4-response element-based or a human aP2 promoter-based Luc reporter vector, along with either chimeric or full-length human PPAR expression plasmids. The non-subtype-selective 2-(4-[2-(3-[2,4-difluorophenyl]-1-heptylureido)ethyl]phenoxy)-2-methyl-butyric acid (GW-2331) and the compounds [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid (L-165041), (4-((2S,5S)-5-(2-(bis(phenylmethyl)amino)-2-oxoethyl)-2-heptyl-4-oxo-3-thiazolidinyl)butyl)-benzoic acid (GW-0072), and indomethacin behaved as partial agonists relative to pioglitazone in full-length human aP2-PPARγ2. Beyond their partial PPARγ agonist properties, these compounds elicited a lower maximal up-regulation of mouse aP2 mRNA in 3T3-L1 adipocytes as compared with pioglitazone; these properties paralleled a time-dependent increase in neutral lipids. By contrast, the selective PPARα agonist 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid (BM-17.0744) neither stimulated the human aP2-PPARα promoter reporter-gene assay, thus demonstrating a specific interaction between PPARγ and the aP2 promoter, nor affected lipogenesis in 3T3-L1 cells. Altogether, these data characterized a functional promoter of the human aP2 gene; its in vitro pharmacological regulation in PPARγ-mediated reporter-gene assay may represent an interesting complement or an alternative to time-consuming procedures aiming at discriminating PPAR ligands with low lipogenic properties.

[1]  J. Beckman,et al.  Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities , 2003, Current opinion in cardiology.

[2]  S. Haffner,et al.  Epidemic obesity and the metabolic syndrome. , 2003, Circulation.

[3]  S. Grundy,et al.  The metabolic syndrome: a practical guide to origins and treatment: Part II. , 2003, Circulation.

[4]  S. Grundy,et al.  The metabolic syndrome , 2003, The Lancet.

[5]  K. Brown,et al.  Effects of a PPAR&ggr; Agonist, GI262570, on Renal Filtration Fraction and Nitric Oxide Level in Conscious Rats , 2003, Journal of cardiovascular pharmacology.

[6]  G. L. Coleman,et al.  Mechanism and Implications of Brown Adipose Tissue Proliferation in Rats and Monkeys Treated with the Thiazolidinedione Darglitazone, a Potent Peroxisome Proliferator-Activated Receptor-γ Agonist , 2003, Journal of Pharmacology and Experimental Therapeutics.

[7]  R. Evans,et al.  Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity , 2003, Cell.

[8]  Bruce A. Johnson,et al.  Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. , 2003, Molecular endocrinology.

[9]  B. Spiegelman,et al.  Genetic Analysis of Adipogenesis through Peroxisome Proliferator-activated Receptor γ Isoforms* , 2002, The Journal of Biological Chemistry.

[10]  B. Staels,et al.  Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[11]  W. Wahli,et al.  Peroxisome proliferator-activated receptors (PPARs): from metabolic control to epidermal wound healing. , 2002, Swiss medical weekly.

[12]  P. Pauwels,et al.  Pharmacological analysis of wild-type α, γ and δ subtypes of the human peroxisome proliferator-activated receptor , 2002, Naunyn-Schmiedeberg's Archives of Pharmacology.

[13]  M. Matsuda,et al.  Enhancement of the Aquaporin Adipose Gene Expression by a Peroxisome Proliferator-activated Receptor γ* , 2001, The Journal of Biological Chemistry.

[14]  M. Matsuda,et al.  PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.

[15]  T. Willson,et al.  Adipose Tissue Resistin Expression Is Severely Suppressed in Obesity and Stimulated by Peroxisome Proliferator-activated Receptor γ Agonists* , 2001, The Journal of Biological Chemistry.

[16]  S. Kliewer,et al.  A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[18]  X. Shen,et al.  Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. , 2000, Diabetes.

[19]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[20]  J. Lehmann,et al.  A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Lazar,et al.  Mechanisms by which Thiazolidinediones Enhance Insulin Action , 1999, Trends in Endocrinology & Metabolism.

[22]  M. Lazar,et al.  A Potent Antidiabetic Thiazolidinedione with Unique Peroxisome Proliferator-activated Receptor γ-activating Properties* , 1998, The Journal of Biological Chemistry.

[23]  J. Lehmann,et al.  N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. , 1998, Journal of medicinal chemistry.

[24]  J. Flier,et al.  Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. , 1997, The Journal of biological chemistry.

[25]  J. Veerkamp,et al.  Assignment of the human adipocyte fatty acid-binding protein gene (FABP4) to chromosome 8q21 using somatic cell hybrid and fluorescence in situ hybridization techniques. , 1997, Genomics.

[26]  J. Lehmann,et al.  Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs* , 1997, The Journal of Biological Chemistry.

[27]  M. D. Leibowitz,et al.  Molecular Cloning, Expression and Characterization of Human Peroxisome Proliferator Activated Receptors γ1 and γ2 , 1996 .

[28]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[29]  B. Spiegelman,et al.  Identification of a fat cell enhancer: Analysis of requirements for adipose tissue‐specific gene expression , 1992, Journal of cellular biochemistry.

[30]  A. Smith,et al.  Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA. , 1989, Biochemistry.

[31]  J. Gordon,et al.  Analysis of the tissue-specific expression, developmental regulation, and linkage relationships of a rodent gene encoding heart fatty acid binding protein. , 1987, The Journal of biological chemistry.

[32]  H. Green,et al.  The nucleotide sequence of three genes participating in the adipose differentiation of 3T3 cells. , 1986, The Journal of biological chemistry.

[33]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[34]  C. Schöfl,et al.  Postmarketing Surveillance Study of the Efficacy and Tolerability of Pioglitazone in Insulin-Resistant Patients with Type 2 Diabetes Mellitus in General Practice , 2003, Clinical drug investigation.

[35]  A. Wolffe,et al.  PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. , 2002, Genes & development.

[36]  Douglas J. A. Adamson,et al.  Diclofenac antagonizes peroxisome proliferator-activated receptor-γ signaling , 2002 .

[37]  A. Wolffe,et al.  PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis , 2002 .

[38]  M. Jaye,et al.  PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway , 2001, Nature Medicine.

[39]  R. Evans,et al.  A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis , 2001 .

[40]  M. D. Leibowitz,et al.  Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. , 1996, Biochemical and biophysical research communications.

[41]  J. Lehmann,et al.  An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). , 1995, The Journal of biological chemistry.